Why scale matters when the disease is slow but relentless Dry age-related macular degeneration progresses in quiet increments ...

A tiny chip, smart glasses and months of training are rewriting what blindness means for older people with failing central ...

Aldeyra Therapeutics reports positive results from phase 2 clinical trial in alcohol-connected hepatitis: Lexington, Massachusetts Thursday, October 30, 2025, 17:30 Hrs [IST] Alde ...

In clinics across Europe, older adults tried a new way to sharpen fading sight. It involved a wafer-thin chip and smart glasses. What the trial shows ...

A wireless photovoltaic implant shows promise in restoring central vision for patients with macular degeneration, enhancing visual acuity and independence.

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® ...

From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches ...

Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of ...

UCSF scientists reveal how the KLF15 protein converts white fat into brown fat that burns energy, offering new hope for ...

Expect to pay at least $1,500 per eye depending on the pro­cedure and the equipment. If you haven't bought a new pair of ...

As the market heads toward USD 527.2 billion by 2035, visual electrophysiology stands at the crossroads of technological advancement and clinical necessity. The ongoing convergence of digital ...

Presenters at the AAO 2025 meeting outlined a future for retinal care that reduces patient burden by reconsidering treatment delivery methods.